CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 245 enrolled
Drug / intervention
biphasic insulin aspart 30 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01215435
NCT01215435Phase 4Completed
CompareCT.gov

An Open Labelled, Randomised, Parallel Trial; Efficacy and Safety Comparison of Two Different Biphasic Insulin Aspart 30 Treatment Initiation Regimens Followed by Intensification in Subjects With Type 2 Diabetes Mellitus Not Achieving Glycaemic Targets on OADs Alone in Iran

Novo Nordisk A/S·interventional·Posted Oct 6, 2010·Updated Oct 30, 2014

In Brief

A Phase 4 clinical trial evaluating biphasic insulin aspart 30 for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 245 participants across 1 site.

Detailed Summary

This trial is conducted in Asia. The aim of this trial is to compare the glycaemic control when subjects initiate a biphasic insulin aspart 30 treatment followed by an intensified treatment if treatment target of HbA1c below 7% is not reached by OAD (oral anti-diabetic drugs) alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesIran
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 6, 2010
Enrollment StartMar 1, 2011
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 15.7 years ago

Interventions

biphasic insulin aspart 30drug

Administered subcutaneously (under the skin) once daily, before breakfast. The trial has 3 treatment phases for both treatment arms

biphasic insulin aspart 30drug

Administered subcutaneously (under the skin) once daily, before dinner. The trial has 3 treatment phases for both treatment arms